Telomir Pharmaceuticals’ shares jumped 35% after promising data showed its lead drug Telomir-1 may offer a safer, dual-action treatment for cancer and aging-related diseases.
Why Telomir Pharmaceuticals Stock Ran Up 35% On Wednesday Night
Where Today's News Shapes Tomorrow
